- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03866811
Reducing Teen Pregnancy in the Emergency Department (ERICA)
Targeting High Risk Teens in the Emergency Department: A User-Informed, Theory-Based Intervention Using Text Messaging to Reduce Teen Pregnancy
Study Overview
Status
Intervention / Treatment
Detailed Description
Emergency Departments (ED) care for 15 million adolescents each year. Adolescents who use the ED are at particularly high risk of unintended pregnancy. To date, no intervention has successfully increased contraception use among this high risk, hard-to-reach ED population.
In this study, the investigators will conduct a pilot randomized controlled trial of a user-informed, theory-based, personalized, interactive, pregnancy prevention text messaging intervention (Dr. Erica) to determine its feasibility, acceptability and potential efficacy. The investigators hypothesize that high risk adolescent female ED patients who receive Dr. Erica will more often initiate contraceptives than those females who receive standard discharge instructions alone.
At baseline and follow-up assessment at 3 months, participants will provide information regarding effective contraception initiation, any contraception at last intercourse, follow up with reproductive preventive health services, and contraception self-efficacy.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Morgan Stanley Children's Hospital Emergency Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- female emergency department patient
- age 14-19 years
- sexually active with males in the past 3 months
Exclusion Criteria:
- currently using any effective form of contraception
- do not own a mobile phone with texting
- are pregnant
- are too ill for participation per the attending physician
- are cognitively impaired
- do not live locally
- do not speak English
- want to "become pregnant in the next year"
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention arm
The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
|
The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations.
(4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
|
|
No Intervention: Control arm
Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Potential Efficacy: Effective Contraception Initiation Rates [Time Frame: Enrollment, 12 Weeks Post-enrollment (2 Weeks Post Close of Intervention)]
Time Frame: 3 months
|
Initiation of effective contraception will be considered positive if participant self-reports initiation of effective contraception at follow up (telephone or online survey). An "effective" form of contraception (as defined by the World Health Organization) includes the following:
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility: Percentage of Refusal
Time Frame: Baseline
|
Percentage of eligible participants who refused
|
Baseline
|
|
Feasibility: Opt Outs Measured Via Mobile Platform
Time Frame: 3 months
|
Percentage of enrolled participants in the intervention group who texted to stop receiving messages.
|
3 months
|
|
Number of Enrolled Participants Who do Not Complete Follow up
Time Frame: 3 months
|
Measurement of the feasibility of Dr. Erica among adolescent female users
|
3 months
|
|
Acceptability: Satisfaction With the Intervention Measured Via Online or Telephone Survey
Time Frame: 3 months
|
Percentage of participants in the intervention group who followed up and answered that they like the program and would recommend it to friends
|
3 months
|
|
Any Sex Over the Past 3 Months
Time Frame: 1 year
|
Self-report of any over the past 3 months.
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory Efficacy Outcome: Number of Participants Who Followed up for Preventative Reproductive Care
Time Frame: 3 months
|
Participants who reported they did not go to the Columbia Family Planning Clinic over the past 3 months and answered "yes" to the question: "Over the past 3 months, have you seen a doctor for medical care?"
In this Outcome, "preventative reproductive care" is defined as any visit to a doctor for the purposes of reproductive health.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lauren S. Chernick, MD, MSc, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAR6781 (Part 2)
- 1K23HD096060-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Montefiore Medical CenterSociety of Family PlanningCompletedContraception | Breastfeeding | Postpartum ContraceptionUnited States
Clinical Trials on Dr. Erica
-
University of PennsylvaniaAmerican Urogynecologic SocietyCompletedCystitis, InterstitialUnited States
-
Duramed ResearchCompletedEndometriosisUnited States
-
Duramed ResearchCompletedStudy to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive BladderUrinary IncontinenceUnited States, Canada
-
LivaNovaCompletedAssess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.Italy, France, Spain, United States, Germany, United Kingdom
-
LivaNovaCompletedTachycardiaFrance, Germany, Portugal, Italy, Canada, United States, Belgium, Netherlands, United Kingdom
-
Hospices Civils de LyonWithdrawn
-
BayerCompleted
-
University of BeykentNot yet recruitingElbow Joint Injuries
-
Rongrong HuaRecruitingArtificial Intelligence | Bone InjuryChina
-
Veyl Ventures LLCKGK Science Inc.Completed